Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06141447 · ClinicalTrials.gov registry record · Phase 2
Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation
A Phase 2 study of Hemorrhage, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06141447: Recruiting Phase 2 study of Hemorrhage, sponsored by University of Colorado, Denver.
NCT06141447 is a Phase 2 study of Hemorrhage that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 150 participants, below the 259-participant average among 20 other Hemorrhage trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06141447, a Phase 2 study of Hemorrhage, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the effectiveness of prophylactic oxytocin on hemorrhage rates for second trimester dilation and evacuation (D\&E) in the clinic setting.
Primary Outcome
Quantitative blood loss greater than or equal to 500 mL or a clinical response to excessive bleeding such as transfusion or hospital admission
Conditions Studied
Interventions
- DRUG Normal saline
- DRUG Oxytocin + normal saline
Study Locations (1)
Colorado
- Comprehensive Women's Health Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-05-02 |
| Est. Completion | 2026-11-02 |
| Phase | Phase 2 |
What NCT06141447 shows while recruiting
NCT06141447 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 259-participant average among 20 other Hemorrhage trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Normal saline is the first listed.
NCT06141447 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06141447 about?
NCT06141447 is a clinical study titled "Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation". The purpose of this study is to assess the effectiveness of prophylactic oxytocin on hemorrhage rates for second trimester dilation and evacuation (D\&E) in the clinic setting.
What is the current status of trial NCT06141447?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-05-02. Estimated completion is 2026-11-02.
What conditions does trial NCT06141447 study?
This clinical trial studies the following conditions: Hemorrhage.
What interventions are being tested in trial NCT06141447?
The interventions under investigation include: Normal saline (DRUG), Oxytocin + normal saline (DRUG).
Who is sponsoring clinical trial NCT06141447?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06141447 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06141447's enrollment target sits among peer trials
150 9th of 20 higher than 12 of 20 other Hemorrhage trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
RECRUITING · Phase 2
-
Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation
COMPLETED · Phase 2
-
NIRS Monitoring in Premature Infants
RECRUITING
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
-
Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes
RECRUITING · Phase 4
-
The Effect of Fluids on Aortic VTI During C-section
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI